APO010 is a novel, investigational systemic chemotherapeutic treatment targeting multiple myeloma, a systemic malignancy in the blood that affects plasma cells.
This recombinant, soluble, hexameric fusion protein consists of three human Fas ligand (FasL) extracellular domains fused to the dimer-forming collagen domain of human adiponectin. It has potential pro-apoptotic and antineoplastic activities.
How it Works
The human immune system can kill cancer cells using a certain type of white blood cells called cytotoxic T lymphocytes (CTLs). One way CTLs kill cancer cells is programmed cell death (apoptosis). A Fas ligand (FasL) on the CTL binds to a death receptor (CD95) on the target cell. This triggers apoptosis.
APO010 is synthesized as a mega FasL consisting of six FasL. The target cell recognizes this as if it were a CTL that binds to the death receptor, triggering apoptosis of the target cell.
APO010 is expected to act in synergy with other cancer immunology agents such as ipilimumab and PD-1/PD-L1 inhibitors.
A Phase 1/2 clinical trial of APO010 is ongoing in Multiple Myeloma (MM) according to plan. In MM, the tumor cells are only available by laboratory separation from other bone marrow cells. The APO-010 DRP® result is influenced by the tumor cell collection procedure, which varies across hospitals. Oncology Venture is currently comparing these collection methods to get the right calibration. No responders have so far been identified in the trial.
In a Phase 1 study in 25 patients with solid tumors, APO010 was well tolerated.
APO010 was found to be highly efficient in multiple myeloma in pre-clinical studies.
Equipment from Oncology Venture’s labs.
Validation of the APO010 DRP is underway in the ongoing Phase 1/2 clinical trial.